Vaccination with Messenger RNA: A Promising Alternative to DNA Vaccination.

No abstract is available for this paper.

• Publication year

  2021

• Venue

  Methods in molecular biology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/978-1-0716-0872-2_2PMID 32827130
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases.

  2019cited by this paper
• Advances in mRNA Vaccines for Infectious Diseases

  2019cited by this paper
• A Facile Method for the Removal of dsRNA Contaminant from In Vitro-Transcribed mRNA

  2019cited by this paper
• Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes

  2019cited by this paper
• Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques

  2019cited by this paper
• A Comparison of Plasmid DNA and mRNA as Vaccine Technologies

  2019cited by this paper
• mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials.

  2019cited by this paper
• Branched-Tail Lipid Nanoparticles Potently Deliver mRNA In Vivo due to Enhanced Ionization at Endosomal pH.

  2019cited by this paper
• Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery.

  2019cited by this paper
• Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses

  2018cited by this paper
• DNA Vaccines—How Far From Clinical Use?

  2018cited by this paper
• Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment.

  2018cited by this paper
• Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity.

  2018cited by this paper
• mRNA vaccines — a new era in vaccinology

  2018cited by this paper
• Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies

  2018cited by this paper
• Neutralization of the Plasmodium-encoded MIF ortholog confers protective immunity against malaria infection

  2018cited by this paper
• Uridine Depletion and Chemical Modification Increase Cas9 mRNA Activity and Reduce Immunogenicity without HPLC Purification

  2018cited by this paper
• An RNA toolbox for cancer immunotherapy

  2018cited by this paper
• Heterologous Immunization With Defined RNA and Subunit Vaccines Enhances T Cell Responses That Protect Against Leishmania donovani

  2018cited by this paper
• Current Concepts of Antigen Cross-Presentation

  2018cited by this paper
• Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

  2017cited by this paper
• Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines

  2017cited by this paper
• Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains

  2017cited by this paper
• Modified mRNA Vaccines Protect against Zika Virus Infection.

  2017cited by this paper
• Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses

  2017cited by this paper
• Zika virus protection by a single low dose nucleoside modified mRNA vaccination

  2017cited by this paper
• Mechanism of action of mRNA-based vaccines

  2017cited by this paper
• Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems

  2017cited by this paper
• A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine

  2017cited by this paper
• Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial.

  2017cited by this paper
• Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treated During Acute HIV Infection

  2017cited by this paper
• Tools for translation: non-viral materials for therapeutic mRNA delivery

  2017cited by this paper
• Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens.

  2017cited by this paper
• Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity

  2017cited by this paper
• Induction of HIV-1 gag specific immune responses by cationic micelles mediated delivery of gag mRNA

  2016cited by this paper
• Immunization of HIV-1-Infected Persons With Autologous Dendritic Cells Transfected With mRNA Encoding HIV-1 Gag and Nef: Results of a Randomized, Placebo-Controlled Clinical Trial

  2016cited by this paper
• Enhanced intranasal delivery of mRNA vaccine by overcoming the nasal epithelial barrier via intra- and paracellular pathways.

  2016cited by this paper
• Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose

  2016cited by this paper
• An mRNA Vaccine Encoding Rabies Virus Glycoprotein Induces Protection against Lethal Infection in Mice and Correlates of Protection in Adult and Newborn Pigs

  2016cited by this paper
• Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

  2016cited by this paper
• Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy

  2016cited by this paper
• RNA-Based Vaccines in Cancer Immunotherapy

  2015cited by this paper
• Self-amplifying mRNA vaccines.

  2015cited by this paper
• Protamine-stabilized RNA as an ex vivo stimulant of primary human dendritic cell subsets

  2015cited by this paper
• Advances in the development of influenza virus vaccines

  2015cited by this paper
• The ReNAissanCe of mRNA-based cancer therapy

  2015cited by this paper
• mRNA-based dendritic cell vaccines

  2015cited by this paper
• Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes.

  2015cited by this paper
• Peptide-MHC-I from Endogenous Antigen Outnumber Those from Exogenous Antigen, Irrespective of APC Phenotype or Activation

  2015cited by this paper
• Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion.

  2015cited by this paper
• Endogenous antigen processing drives the primary CD4+ T cell response to influenza

  2015cited by this paper
• mRNA-based therapeutics — developing a new class of drugs

  2014cited by this paper
• Production and purification of plasmid DNA vaccines: is there scope for further innovation?

  2014cited by this paper
• Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines.

  2013cited by this paper
• Delivery materials for siRNA therapeutics.

  2013cited by this paper
• A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients.

  2013cited by this paper
• Rapidly produced SAM® vaccine against H7N9 influenza is immunogenic in mice

  2013cited by this paper
• A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption.

  2012cited by this paper
• mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients

  2012cited by this paper
• Nonviral delivery of self-amplifying RNA vaccines

  2012cited by this paper
• Vaccination of immunocompromised patients.

  2012cited by this paper
• Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection

  2012cited by this paper
• Intradermal Electroporation of Naked Replicon RNA Elicits Strong Immune Responses

  2012cited by this paper
• Developing mRNA-vaccine technologies

  2012cited by this paper
• Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA

  2011cited by this paper
• Messenger RNA-based Vaccines With Dual Activity Induce Balanced TLR-7 Dependent Adaptive Immune Responses and Provide Antitumor Activity

  2011cited by this paper
• DNA vaccines: an historical perspective and view to the future

  2011cited by this paper
• The combination of 4‐1BBL and CD40L strongly enhances the capacity of dendritic cells to stimulate HIV‐specific T cell responses

  2011cited by this paper
• Intranasal vaccination with messenger RNA as a new approach in gene therapy: Use against tuberculosis

  2010cited by this paper
• Directly Transfected Langerin+ Dermal Dendritic Cells Potentiate CD8+ T Cell Responses following Intradermal Plasmid DNA Immunization

  2010cited by this paper
• Direct Presentation Is Sufficient for an Efficient Anti-Viral CD8+ T Cell Response

  2010cited by this paper
• Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy.

  2010cited by this paper
• In situ expression of tumor antigens by messenger RNA-electroporated dendritic cells in lymph nodes of melanoma patients.

  2009cited by this paper
• Single-Step Antigen Loading and Activation of Dendritic Cells by mRNA Electroporation for the Purpose of Therapeutic Vaccination in Melanoma Patients

  2009cited by this paper
• Direct Injection of Protamine-protected mRNA: Results of a Phase 1/2 Vaccination Trial in Metastatic Melanoma Patients

  2009cited by this paper
• Adeno-associated virus vector integration.

  2009cited by this paper
• Upstream processing of plasmid DNA for vaccine and gene therapy applications.

  2008cited by this paper
• Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA.

  2008cited by this paper
• CD83 expression on dendritic cells and T cells: Correlation with effective immune responses

  2007cited by this paper
• Potential of Transfected Muscle Cells to Contribute to DNA Vaccine Immunogenicity1

  2007cited by this paper
• Effective induction of anti-melanoma immunity following genetic vaccination with synthetic mRNA coding for the fusion protein EGFP.TRP2

  2006cited by this paper
• Therapeutic anti‐tumor immunity triggered by injections of immunostimulating single‐stranded RNA

  2006cited by this paper
• Inadvertent germline transmission of AAV2 vector: findings in a rabbit model correlate with those in a human clinical trial.

  2006cited by this paper
• A universal vaccine for serogroup B meningococcus.

  2006cited by this paper
• Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination

  2005cited by this paper
• Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand.

  2005cited by this paper
• Human clinical trials of plasmid DNA vaccines.

  2005cited by this paper
• Toll‐like receptor‐dependent activation of several human blood cell types by protamine‐condensed mRNA

  2005cited by this paper
• Cotransfection of dendritic cells with RNA coding for HER-2/neu and 4-1BBL increases the induction of tumor antigen specific cytotoxic T lymphocytes

  2005cited by this paper
• The injection of plasmid DNA in mouse muscle results in lifelong persistence of DNA, gene expression, and humoral response

  2004cited by this paper
• Cancer immunotherapy with mRNA‐transfected dendritic cells

  2004cited by this paper
• Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation

  2004cited by this paper
• DNA vaccines and their application against parasites--promise, limitations and potential solutions.

  2004cited by this paper
• Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer.

  2004cited by this paper
• A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency.

  2003cited by this paper
• T cell fitness determined by signal strength

  2003cited by this paper
• Immunology of bacterial polysaccharide antigens.

  2003cited by this paper
• Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells.

  2003cited by this paper
• Gene Transfer to Subdermal Tissues via a New Gene Gun Design

  2003cited by this paper
• Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors.

  2002cited by this paper

• Accelerate the Highly Efficient Development of mRNA Vaccines Through Advanced Computational Methods

  2026cites this paper
• Innovations in cancer treatment as novel potential and the myth of personalized vaccines, immunotherapy, CRISPR/Cas9, and bacteriotherapy as promising therapeutic strategies

  2025cites this paper
• Messenger RNA vaccines in the prevention of allergic diseases

  2025cites this paper
• A Comprehensive Review of Our Understanding and Challenges of Viral Vaccines against Swine Pathogens

  2024cites this paper
• Non-clinical safety assessment of novel drug modalities: Genome safety perspectives on viral-, nuclease- and nucleotide-based gene therapies.

  2024cites this paper
• DNASCANNER v2: A Web-Based Tool to Analyze the Characteristic Properties of Nucleotide Sequences

  2024cites this paper
• Feline Infectious Peritonitis mRNA Vaccine Elicits Both Humoral and Cellular Immune Responses in Mice

  2024cites this paper
• Producing Plasmid DNA Template for Clinical Grade RNA Vaccine Manufacture.

  2024cites this paper
• A comprehensive comparison of DNA and RNA vaccines.

  2024cites this paper
• Session 4: mRNA and Self-Amplifying RNA (saRNA): Opportunities for Disease Prevention and Therapy

  2024cites this paper
• Evolution and Progress of mRNA Vaccines in the Treatment of Melanoma: Future Prospects

  2023cites this paper
• Transitional Insight into the RNA-Based Oligonucleotides in Cancer Treatment

  2023cites this paper
• The use of RNA-based treatments in the field of cancer immunotherapy

  2023cites this paper
• Transcriptional Targeting of Dendritic Cells Using an Optimized Human Fascin1 Gene Promoter

  2023cites this paper
• Navigating the horizon of mRNA vaccines: Tracing their evolution, ensuring safety, and unveiling therapeutic potential

  2023cites this paper
• The Silver Lining of the COVID-19 Pandemic: Fast-Tracked Vaccine Production and Approval

  2023cites this paper
• mRNA Vaccine-A New Cancer Treatment Strategy.

  2023cites this paper
• Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies

  2022cites this paper
• Influenza vaccines: where we are, where we are going

  2022cites this paper
• Towards Tabula Gallus

  2022cites this paper
• Ferroptosis: regulation by competition between NRF2 and BACH1 and propagation of the death signal

  2022cites this paper
• Harnessing DNA for Immunotherapy: Cancer, Infectious Diseases, and Beyond

  2022cites this paper
• mRNA-based vaccine candidate COReNAPCIN® induces robust humoral and cellular immunity in mice and non-human primates

  2022cites this paper
• mRNA cancer vaccines: Advances, trends and challenges

  2022cites this paper
• mRNA- and Adenovirus-Based Vaccines against SARS-CoV-2 in HIV-Positive People

  2022cites this paper
• Nanodelivery of nucleic acids

  2022cites this paper
• Protective Immune Responses Induced by an mRNA-LNP Vaccine Encoding prM-E Proteins against Japanese Encephalitis Virus Infection

  2022cites this paper
• SARS-CoV-2 mRNA-vaccine candidate; COReNAPCIN®, induces robust humoral and cellular immunity in mice and non-human primates

  2022cites this paper
• An OX40L mRNA vaccine inhibits the growth of hepatocellular carcinoma

  2022cites this paper
• Third-Generation Vaccines: Features of Nucleic Acid Vaccines and Strategies to Improve Their Efficiency

  2022cites this paper
• Future perspectives on swine viral vaccines: where are we headed?

  2021cites this paper
• Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges, and Opportunities

  2021cites this paper
• VirVACPRED: A Web Server for Prediction of Protective Viral Antigens

  2021cites this paper
• mRNA Vaccines: Why Is the Biology of Retroposition Ignored?

  2021influential citation
• mRNA vaccines: Why and how they should be modified

  2021cites this paper
• Dynamic mRNA polyplexes benefit from bioreducible cleavage sites for in vitro and in vivo transfer.

  2021cites this paper
• Platforms for Production of Protein-Based Vaccines: From Classical to Next-Generation Strategies

  2021cites this paper
• Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic

  2021cites this paper
• COVID-19 and Preparing for Future Ecological Crises: Hopes from Metagenomics in Facing Current and Future Viral Pandemic Challenges

  2021cites this paper
• Heartworm disease – Overview, intervention, and industry perspective

  2021cites this paper
• Nanoparticle-Mediated Cytoplasmic Delivery of Messenger RNA Vaccines: Challenges and Future Perspectives

  2021cites this paper
• Identification of a Five-Autophagy-Related-lncRNA Signature as a Novel Prognostic Biomarker for Hepatocellular Carcinoma

  2021cites this paper
• Virus Eradication and Synthetic Biology: Changes with SARS-CoV-2?

  2021influential citation
• Nanotechnology and Nanomedicine-Based Strategies in Parasitic Infection

  year unknowncites this paper
• MIT Open Access

  year unknowncites this paper